{"id":3904,"date":"2025-09-22T12:34:22","date_gmt":"2025-09-22T10:34:22","guid":{"rendered":"https:\/\/www.esptcongress.org\/?page_id=3904"},"modified":"2025-09-22T15:22:25","modified_gmt":"2025-09-22T13:22:25","slug":"chandler-scott","status":"publish","type":"page","link":"https:\/\/www.esptcongress.org\/index.php\/chandler-scott\/","title":{"rendered":"Chandler Scott"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column width=&#8221;1\/4&#8243;]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">.shortcode-single-image-wrap.shortcode-single-image-64d6a8c4185e88508daf24e4da9e19dd.enable-bg-rollover .rollover i,\n.shortcode-single-image-wrap.shortcode-single-image-64d6a8c4185e88508daf24e4da9e19dd.enable-bg-rollover .rollover-video i {\n  background: -webkit-linear-gradient();\n  background: linear-gradient();\n}\n.shortcode-single-image-wrap.shortcode-single-image-64d6a8c4185e88508daf24e4da9e19dd .rollover-icon {\n  font-size: 32px;\n  color: #ffffff;\n  min-width: 44px;\n  min-height: 44px;\n  line-height: 44px;\n  border-radius: 100px;\n  border-style: solid;\n  border-width: 0px;\n}\n.dt-icon-bg-on.shortcode-single-image-wrap.shortcode-single-image-64d6a8c4185e88508daf24e4da9e19dd .rollover-icon {\n  background: rgba(255,255,255,0.3);\n  box-shadow: none;\n}<\/style><div class=\"shortcode-single-image-wrap shortcode-single-image-64d6a8c4185e88508daf24e4da9e19dd alignnone  vc_custom_1758537187558 enable-bg-rollover dt-icon-bg-off\" ><div class=\"shortcode-single-image\"><div class=\"fancy-media-wrap  layzr-bg\" style=\"\"><img fetchpriority=\"high\" decoding=\"async\" class=\"preload-me lazy-load aspect\" src=\"data:image\/svg+xml,%3Csvg%20xmlns%3D&#39;http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg&#39;%20viewBox%3D&#39;0%200%20500%20500&#39;%2F%3E\" data-src=\"https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Chandler_foto-2-500x500.png\" data-srcset=\"https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Chandler_foto-2-500x500.png 500w, https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Chandler_foto-2-1000x1000.png 1000w\" loading=\"eager\" sizes=\"(max-width: 500px) 100vw, 500px\" width=\"500\" height=\"500\"  data-dt-location=\"https:\/\/www.esptcongress.org\/index.php\/speakers\/chandler_foto-2\/\" style=\"--ratio: 500 \/ 500;\" alt=\"\" \/><\/div><\/div><\/div><div class=\"standard-arrow list-divider bullet-top\"><ul>\n<li>G Scott Chandler, M.D.<br \/>\nGlobal Head, Precision Safety,<br \/>\nProduct DevelopmentHoffmann La Roche<\/li>\n<\/ul>\n<\/div>[\/vc_column][vc_column width=&#8221;3\/4&#8243;]<div id=\"ultimate-heading-669869f0da59d6df3\" class=\"uvc-heading ult-adjust-bottom-margin ultimate-heading-669869f0da59d6df3 uvc-4937 color-title accent-title-color uvc-heading-default-font-sizes\" data-hspacer=\"no_spacer\"  data-halign=\"left\" style=\"text-align:left\"><div class=\"uvc-heading-spacer no_spacer\" style=\"top\"><\/div><div class=\"uvc-main-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-669869f0da59d6df3 h2'  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}' ><h2 style=\"--font-weight:theme;\">CV<\/h2><\/div><div class=\"uvc-sub-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-669869f0da59d6df3 .uvc-sub-heading '  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}'  style=\"font-weight:normal;\">Dr. Chandler leads Precision Safety at Roche, which focuses on characterizing the patient-centric drivers of response to therapy in order to optimize benefit\/risk balance of our medicines.\u00a0 The group works across all therapeutic areas and phases of development and commercialization, through extensive interaction with internal collaborators and external partners.\u00a0 By leveraging high-dimensional data (e.g., genomics, immunophenotyping), applying advanced analytics (e.g., machine learning, natural language processing), and deploying novel technologies (e.g., organoids, remote digital monitoring), the team seeks to develop innovative approaches to bringing the right medicine to the right patient at the right time, for every patient, everywhere.\u00a0 Dr. Chandler attended medical and graduate school at the University of California, Irvine, where he trained in Medicine and Toxicology.\u00a0 He then attended the University of California, Los Angeles, and underwent further training in General Surgery, Surgical Oncology, and Tumor Immunology.\u00a0 Over the last 20 years, Dr. Chandler has held multiple roles in the biotechnology and pharmaceutical industry with a focus on drug safety, translational science, and precision medicine.<\/div><\/div><div id=\"ultimate-heading-950669f0da59d6e86\" class=\"uvc-heading ult-adjust-bottom-margin ultimate-heading-950669f0da59d6e86 uvc-1509 color-title accent-title-color uvc-heading-default-font-sizes\" data-hspacer=\"no_spacer\"  data-halign=\"left\" style=\"text-align:left\"><div class=\"uvc-heading-spacer no_spacer\" style=\"top\"><\/div><div class=\"uvc-main-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-950669f0da59d6e86 h2'  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}' ><h2 style=\"--font-weight:theme;margin-top:50px;\">ABSTRACT<\/h2><\/div><div class=\"uvc-sub-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-950669f0da59d6e86 .uvc-sub-heading '  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}'  style=\"font-weight:normal;\">The prime directive of medicine is to first do no harm, yet there remains an unmet need to develop medicine and diagnostic strategies that truly optimize benefit\/risk balance at the individual patient level.\u00a0 By understanding the multiple patient-specific factors that influence response to medicines, the potential to develop truly personalized treatment strategies for patients around the world becomes achievable.\u00a0 The session will review recent findings from exploratory analyses on the factors impacting response to cancer immunotherapy.\u00a0 Highlights include impact of germline genetics such a polygenic risk for autoimmune disease and HLA variants; the role of dynamic changes in immune profiles following treatment; and how tumor biology and the presence or absence of circulating tumor DNA may are associated with different responses to treatment.\u00a0 The goal of the session is to share emerging insights and a potential framework for precision oncology care that considers the patient-specific factors as well as the tumor-specific factors that could be leveraged to optimize benefit\/risk balance across treatments.<\/div><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column width=&#8221;1\/4&#8243;][\/vc_column][vc_column width=&#8221;3\/4&#8243;][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3904","page","type-page","status-publish","hentry","description-off"],"_links":{"self":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/comments?post=3904"}],"version-history":[{"count":5,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3904\/revisions"}],"predecessor-version":[{"id":3951,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3904\/revisions\/3951"}],"wp:attachment":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/media?parent=3904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}